Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

693
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
693
Drug Therapy01:28

Drug Therapy

440
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
440
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

960
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
960
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.5K
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

1.2K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.

Future oncology (London, England)·2025
Same author

The burden of some of the most common zoonoses in primary care: a population-based study in Italy.

Postgraduate medical journal·2025
Same author

Human monoclonal antibodies targeting subdominant meningococcal antigens confer cross-protection against gonococcus.

Science translational medicine·2025
Same author

Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.

Diabetes & metabolic syndrome·2025
Same author

State of the Art and Consensus Statements by Healthcare Providers, Patients, and Caregivers on Continuous Glucose Monitoring in Liver Glycogen Storage Diseases.

Journal of inherited metabolic disease·2025
Same author

Immunomodulatory effects of dental pulp stem cells on lymphocytes and monocytes from patients with rheumatoid arthritis.

Clinical and experimental rheumatology·2025

Related Experiment Video

Updated: Apr 23, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

20.2K

Towards a framework for treatment effectiveness in schizophrenia.

Georg Juckel1, Andrea de Bartolomeis2, Philip Gorwood3

  • 1Department of Psychiatry, LWL-University Hospital, Ruhr-University Bochum, Bochum, Germany.

Neuropsychiatric Disease and Treatment
|October 7, 2014
PubMed
Summary

This study proposes a new five-domain framework to help psychiatrists assess antipsychotic treatment effectiveness in schizophrenia. This patient-centered approach aims to improve clinical practice and patient outcomes.

Keywords:
antipsychoticassessment scalesfunctioningmental illnesssatisfaction

More Related Videos

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

65
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

20.2K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

65
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Area of Science:

  • Psychiatry and Psychopharmacology
  • Schizophrenia Treatment Research

Background:

  • Effective antipsychotic treatment is crucial for schizophrenia management.
  • Second-generation antipsychotics offer symptomatic benefits but carry metabolic risks.
  • Defining and measuring treatment effectiveness in schizophrenia is complex.

Purpose of the Study:

  • To develop a practical framework for assessing antipsychotic treatment effectiveness in schizophrenia.
  • To guide psychiatrists in evaluating treatment outcomes beyond symptom reduction.

Main Methods:

  • A panel of 12 psychiatrists and psychopharmacologists developed an initial framework.
  • The framework was refined based on feedback from European psychiatrists.
  • The study involved a consensus-building approach.

Main Results:

  • A globally applicable framework for assessing antipsychotic treatment effectiveness was proposed.
  • The framework includes five key domains: symptomatic remission/treatment retention, affective symptoms, cognitive functioning, treatment satisfaction, and personal/social functioning.

Conclusions:

  • The proposed five-domain framework can aid psychiatrists in assessing treatment effectiveness.
  • This patient-centered approach aims to enhance clinical practice for schizophrenia patients.
  • The framework promotes a holistic evaluation of antipsychotic treatment outcomes.